

Application No.: 09/809,638

2

Docket No.: 511582003500

REMARKS

The reproduction of an electronic mail message discussed in the previous response was inadvertently omitted from the filing. This response supplies that message.

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 511582003500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 3, 2005

Respectfully submitted,

By 

James J. Mullen III, Ph.D.

Registration No.: 44,957

MORRISON & FOERSTER LLP

12531 High Bluff Drive

Suite 100

San Diego, California 92130-2040

(858) 720-7940

sd-287649

AUG-31-2005 14:34

AGENSYS

310 820 7890 P.03/03

Popp, Shane

From: Mitchell, Steve
Sent: Wednesday, January 03, 2001 1:43 PM
To: Scientists
Subject: 125P5C8 reagents.

Colleagues,

The Company reagent for 125P5C8 (124P1B7/139P3A1) is pasted. It is a PCR based pCR2.1/TA clone(prostate) with three point differences from the Japanese (colon) reported hypothetical sequence. Two point are conserved for translation whereas the third point difference gives an amino acid change near the 3 prime end. This is verified with genomic sequencing.

>125P5C8(124P1B7/139P3A1) pCR2.1 subclone
 CGATGACCTCGCTGTGGAGAGAAATCCTCTTGGAGTGGCTGCTGGGATGTGTTTCTTGCTCTCTACCATGACCTGGGACCGATG
 ATCTATTACTTCTCTTCTGCAAACTAGAACTCACTGGGCTTGAAGGTTTTAGTATAGCATTCTTTCTCCAAATATTCCTAACAATTACT
 CCTTCTCGAAATTGGTTAAACAAGAAGTGGATGCTAAACCTGTCTGAGGATAATCACTATTGGCAGCATAGCCCTCTTCAGGCTGCCA
 AATGCCAAAGATTCCGACTGATGGTCTTTCGGCTTGGGGTGTCTTCTCACTGATAGTGCAAGCTGTGACTTGTGGTGGGGAAGTCAT
 TTGCAAAAGGTACCTCAGAATTTGGGATTCATTTAGGACAGATTGTCTTGTGTTCTACGCATATGGTATACTTCACTAAACCCAAAT
 CTGGAGTTATCAGATGTCCAACAAGTGTACTGATCATTAAAGTCCATAGCCACACTGTATCGTATTGGCAGACAGTGGTGATCGAG
 TAAACCTGAAGAAAAAGAACCACTGGTGAGGTAGCCACGGGGATGGCTCTAGACCCAACTGGCTGCTGGCAGGGGGTCTGTTTTGGT
 AGCCTTGTGTTCTTCAAGGCTGGTTTTGGGAGAAGTCTCTTGTCTCAGATGGGCGAGTGAAGTGGCATCCACATCCAGGGGCT
 AGATCCTAACCCCACTTTGGAGGTGCACTGCTGTGCTTGGCAAGTGGATGATGCTTCCATCTGTTTGTGGTTTTCTGGTGGTACTGG
 TTTGATCTGGTGGGTTACAGGAACAGCTTCAGCTGCGGGGCTCCTTTACCTGCACAGATGGGCACTGCTGTGCTGTGCTGTGCT
 TCGCCATCTTACTGTCATCCATGTGGCCCCCAACACTTTGGACACCTTATTAACTCAGGGACAAACCTGGGAAAACCATGACCAATTG
 CCATGATATTTTATCTTCTAGAAATATTTCTGTGCTGTGGTGCACAGCTTTTAAGTTTGTCCCAGGAGGTGCTCAGGCTAGAGAAAG
 ATCAGAGATGCTCTTTGGGGACAATGATGTTAATTATCGGGCTGAATATGCTATTTGGTCTCTAGAAAAGAACTTGACTTCTCTTCA
 ACAAAAAGCAAGTTCTAAAGTGCTTTTCAAGAAAGAGTGA AAAAATACATGAAAGTTTCTGTGCTGCTTGTGTTGGTGGGATTGTTGG
 GATTAGGACTACGGCATAAAGCTTATGAGAGAAAGTGGCCAAAGTGCACCAACCAAAAGAGTCTGCTGCTGCCATCTGGCCTTTCT
 AGGTTTGGATATGACAAATGAAGGGTGGTCTAGTCTAGAAAGATCAGCTCAGCTGCTCAATGAAACAGGTGCAGATTTCTAAGCAAT
 TTGGAGAGTGATGCTTCTAAGCCCATATGATGAGGAACATGACTTAACCATGTGGCTAGGGGAAAAGTTGGGTTCTATACAGACTTT
 GGTCCAAGCACAAAGGTATACACTTGGGGGATATGGCTTTGTCAAGATACCCAAATGTGAATCTGAGCATCACTTCTTCCGCTGA
 CCAGAGGGGCGAGATCGCACCAGCCATCAGATTGACCGTTAACATTTCCGGGCAAGCTGGTGATTTTGTGCTGACACACTTTGGGAA
 ATATATCACTTCAGCACCTGGCTCCAGAGATATCTACAGCTCACTGAACATGGCAATGTGAAGGATCTGACAGCACTGATCATGA
 CAGATGGTGTGAATACATTATGTATCGAGGGCTGATCAGGTTGGGTTTGAAGGATTCGCCATGCTGAATGAGTATTGAGAAAT
 TCAGATGGGCAAAATTTAGGATCCCTGATGACCCCAATTATAGAGACAACCCAGAAAGTGGTCATAGACCAAGAGAGGTTCTGTA
 GAAAATTCATTTAATCCAGATTGATGCTTACAAAGAACCAATATGAAAACAACCATCATTTTCATATGAATACTCCAAAT
 ACTTTTATGAAAC

>125P5C8(124P1B7/139P3A1) pCR2.1 subclone
 MTLWREILLESLGCVSWSLYHDLGPMIYYFLQTLELTGLEGFSAFLSPIFLTITPFWKLVNKKWMLTLRLITIGSIABFOAPNAKLRLM
 LALGVSSSLVQAVTWVWSSHLQRYLRJWGFILOVLVLRWYTSLNPIWSYQMSNKVILTSAIATLDRIGTDGDCSKPEEKKTGEVA
 GMASTRPNWLLAGAAPGSLVLTWVYFGEVSLVSRVWVSGHPHPGDPNPFPGGAVLLCLASGLMLPSCLVFRGTGLWVWVTGTASAA
 LLYUHTWAAAVSGCVFAIFTASLWMPQTLGLHNSGTNPCKMTIAMIFVLEIFFCAWCTAFKVPVGGVYARERSDYLSTMMLIIGLNNML
 GPKKNLDLLLTQKNSSKVLFRKEBEKYMKLFLWLVLVGVLGLGLRHKAYERLGLKVAPTKVEVSAAMWPFYRGDYNEGWSSLSERSAHL
 TEGADFIITSSDASKPYMGNNDLTMWLGEKLFYTFDGPSTRYHTWGMIALSRYPVIVKSEHLLPSPEGEIAPAITLTYNISOKLVDFV
 HFGNHEDDLDRKLQAIYVSKLLKSSBNQVILGYTSAPGSDRYLQLTEHGNVKIDSTOHDHRCWEYIMYRGURLGYARISHAELSDSEI
 MAKFRIPDDPTNYRDNQKVVIDHREVSEKIHFNPRFGSYKEGHYENNHIFHMINTPKYFL

Steve Chappell Mitchell
Associate Scientist
UroGenesys
1701 Colorado Avenue
Santa Monica, CA 90404
Tel (310)820-8029 x281
Fax (310)820-8488
Email smitchell@urogenesys.com
Url www.urogenesys.com

BEST AVAILABLE COPY